There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of 18F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy 18F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus–related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.
*Y.S. is a Visiting Senior Research Fellow, UT Southwestern Medical Center, Dallas, TX;
†K.Z. is an Associate Professor of Radiology, McMaster University, Hamilton, Ontario, Canada;
‡E.M. is an Associate Professor of Radiology, Stanford University Medical Center, Stanford, CA;
§D.L.C. is an Associate Professor of Radiology, Washington University School of Medicine, St Louis, MO;
∥H.N. is a Professor of Radiology, University of British Columbia, Vancouver, British Columbia, Canada;
¶R.D.N. is a Nuclear Medicine Physician, Kaiser Permanente, Santa Clara, CA; and
**R.M.S. is a Professor of Radiology, Harold Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
All authors, faculty, and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity.
Received for publication November 24, 2017; revision accepted July 5, 2018.
Correspondence to: Rathan M. Subramaniam, MD, PhD, MPH, Department of Radiology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390–8896. E-mail: rathan.subramaniam@UTsouthwestern.edu.